We’ve written numerous time about outcomes-based contracting. The concept has been around for well over a decade….. yet the practice has experienced slow uptake…. for one reason…. It’s
…………………….catching up on FDA approvals The FDA recently approved a new ORAL therapy, Vafseo (vadadustat) from Akebia Therapeutics, for the treatment of anemia due to
Cardinal Health recently published a very slick report on the State of Biosimilars. We’ve heard so much about biosimilars (even from this esteemed reporting source)
………. catching up on FDA approvals The FDA recently approved a new subcutaneous therapy, Winrevair (sotatercept-csrk) from Merck & Co. Winrevair is an activin signaling inhibitor
…………….catching up with FDA approvals The FDA has approved a new infused therapy, Tevimbra (tislelizumab-jsgr) from BiGene, indicated for the treatment of adult patients with
……. catching up on FDA approvals The FDA recently approved another tocilizumab biosimilar, Tyenne (tocilizumab-aazg) from Fresenius Kabi, indicated for Rheumatoid arthritis, Giant cell arteritis,
Several weeks ago the winners of the 2023 annual specialty pharmacy Patient Choice Awards beauty pageant were announced. Sadly, the coverage of the event was limited
………. catching up on FDA approvals The FDA has granted expanded indications for a therapy initially approved in 2021 adding to the rapidly growing toolkit
Last week the FDA approved yet another biosimilar…… oh wait…. it was a biosimilar with an indication for not one, but TWO rare diseases. That makes
…………catching up on FDA approvals The FDA recently approved a new oral solution, Livmarli (maralixibat) from Mirum Pharmaceuticals, Inc, indicated for the treatment of cholestatic
